Back

Reduction in heart failure hospitalizations by sacubitril/valsartan; a post-hoc analysis of the PARALLAX trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: HFpEF and HFmrEF: what’s new in treatment? Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Rolf Wachter

University hospital Leipzig AoR, Leipzig (Germany)

4 More presentations in this session

Presentation thumbnail
Trimetazidine in heart failure with preserved ejection fracton: a randomized, double-blind cross-over trial
Mr A. van de Bovenkamp (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
Professor J. Butler (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Association between use of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors and beta-blockers and outcome in real-world heart failure and mildly reduced ejection fraction
Doctor F. Lindberg (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
The therapeutic potential of relaxin for heart failure with preserved ejection fraction
Doctor G. Salama (Pittsburgh, US)
Abstract Slides Video

Access the full session

Session thumbnail
HFpEF and HFmrEF: what’s new in treatment?

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
thumbnail
Congress Presentation
Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF
thumbnail
Congress Presentation
Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources